8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To assess the performance of imaging features, including radiomics texture features, in predicting histopathologic tumor grade, AJCC stage, and outcomes [time to recurrence (TTR) and overall survival (OS)] in patients with intrahepatic cholangiocarcinoma (ICC).

          Methods

          Seventy-three patients (26 M/47F, mean age 63y) with pre-operative imaging (CT, n = 37; MRI, n = 21; CT and MRI, n = 15] within 6 months of resection were included in this retrospective study. Qualitative imaging traits were assessed by 2 observers. A 3rd observer measured tumor apparent diffusion coefficient (ADC), enhancement ratios (ERs), and Haralick texture features. Blood biomarkers and imaging features were compared with histopathology (tumor grade and AJCC stage) and outcomes (TTR and OS) using log-rank, generalized Wilcoxon, Cox proportional hazards regression, and Fisher exact tests.

          Results

          Median TTR and OS were 53.9 and 79.7 months. ICC recurred in 64.4% (47/73) of patients and 46.6% (34/73) of patients died. There was fair accuracy for some qualitative imaging features in the prediction of worse tumor grade (maximal AUC of 0.68 for biliary obstruction on MRI, p = 0.032, observer 1) and higher AJCC stage (maximal AUC of 0.73 for biliary obstruction on CT, p = 0.002, observer 2; and AUC of 0.73 for vascular involvement on MRI, p = 0.01, observer 2). Cox proportional hazards regression analysis showed that CA 19–9 [hazard ratio (HR) 2.44/95% confidence interval (CI) 1.31–4.57/ p = 0.005)] and tumor size on imaging (HR 1.13/95% CI 1.04–1.22/ p = 0.003) were significant predictors of TTR, while CA 19–9 (HR 4.08/95% CI 1.75–9.56, p = 0.001) and presence of metastatic lymph nodes at histopathology (HR 2.86/95% CI 1.35–6.07/ p = 0.006) were significant predictors of OS. On multivariable analysis, satellite lesions on CT (HR 2.79/95%CI 1.01–7.15/ p = 0.032, observer 2), vascular involvement on MRI (HR 0.10/95% CI 0.01–0.85/ p = 0.032, observer 1), and texture feature MRI variance (HR 0.55/95% CI 0.31–0.97, p = 0.040) predicted TTR once adjusted for the independent predictors CA 19–9 and tumor size on imaging. Several qualitative and quantitative features demonstrated associations with TTR, OS, and AJCC stage at univariable analysis (range: HR 0.35–19; p < 0.001–0.045), however none were predictive of OS at multivariable analysis when adjusted for CA 19–9 and metastatic lymph nodes ( p > 0.088).

          Conclusions

          There was reasonable accuracy in predicting tumor grade and higher AJCC stage in ICC utilizing certain qualitative and quantitative imaging traits. Serum CA 19–9, tumor size, presence of metastatic lymph nodes, and qualitative imaging traits of satellite lesions and vascular involvement are predictors of patient outcomes, along with a promising predictive ability of certain quantitative texture features.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

          T. Patel (2001)
          Clinical observations suggest a recent increase in intrahepatic biliary tract malignancies. Thus, our aim was to determine recent trends in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Reported data from the Surveillance, Epidemiology, and End Results (SEER) program and the United States Vital Statistics databases were analyzed to determine the incidence, mortality, and survival rates of primary intrahepatic cholangiocarcinoma. Between 1973 and 1997, the incidence and mortality rates from intrahepatic cholangiocarcinoma markedly increased, with an estimated annual percent change (EAPC) of 9.11% (95% CI, 7.46 to 10.78) and 9.44% (95%, CI 8.46 to 10.41), respectively. The age-adjusted mortality rate per 100,000 persons for whites increased from 0.14 for the period 1975-1979 to 0.65 for the period 1993-1997, and that for blacks increased from 0.15 to 0.58 over the same period. The increase in mortality was similar across all age groups above age 45. The relative 1- and 2-year survival rates following diagnosis from 1989 to 1996 were 24.5% and 12.8%, respectively. In conclusion, there has been a marked increase in the incidence and mortality from intrahepatic cholangiocarcinoma in the United States in recent years. This tumor continues to be associated with a poor prognosis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

            The incidence of intrahepatic cholangiocarcinoma (ICC) has been reported to be increasing in the USA. The aim of this study is to examine whether this is a true increase or a reflection of improved detection or reclassification. Using data from the Surveillance Epidemiology and End Results (SEER) program, incidence rates for ICC between 1975 and 1999 were calculated. We also calculated the proportions of cases with each tumor stage, microscopically confirmed cases, and the survival rates. A total of 2864 patients with ICC were identified. The incidence of ICC increased by 165% during the study period. Most of this increase occurred after 1985. There were no significant changes in the proportion of patients with unstaged cancer, localized cancer, microscopic confirmation, or with tumor size <5 cm during the period of the most significant increase. The 1-year survival rate increased significantly from 15.8% in 1975-1979 to 26.3% in 1995-1999, while 5-year survival rate remained essentially the same (2.6 vs. 3.5%). The incidence of ICC continues to rise in the USA. The stable proportions over time of patients with early stage disease, unstaged disease, tumor size <5 cm, and microscopic confirmation suggest a true increase of ICC.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

              The age-standardized mortality rate for hepatocellular carcinoma is increasing in several countries. However, in England and Wales we previously reported an increase in mortality rates from intrahepatic cholangiocarcinoma. Trends in cholangiocarcinoma in most other industrialized countries are unknown. To further study trends in hepatobiliary and pancreatic tumours, we analysed mortality data from the United States, Japan, Australia and Europe. Age-standardized mortality rates for men and women for subcategories of liver tumours, tumours of the gall bladder and extrahepatic biliary tree and pancreas from 1979 to 1998 were obtained from the World Health Organization mortality database. We confirmed previously reported increases in hepatocellular carcinoma, but also found increases in other countries, particularly Australia (3-year average rise from 1.20 to 2.27, men). Mortality for intrahepatic cholangiocarcinoma increased in men in all countries studied, with the largest increases in Australia (from 0.10 to 0.70) and England and Wales (from 0.20 to 0.83). We present a hitherto unreported rise in age-standardized mortality rates from intrahepatic cholangiocarcinoma across four continents. The cause remains uncertain. An impact on the observed trends of improved diagnostic techniques and death certificate misclassification cannot be completely ruled out. Future research should include epidemiological studies to examine possible case-clustering and investigation of potential aetiological and host factors.
                Bookmark

                Author and article information

                Contributors
                Michael.J.King@mountsinai.org
                Stefanie.Hectors@mountsinai.org
                Karen.Lee@mountsinai.org
                Olamide.Omidele@mountsinai.org
                James.Babb@nyulangone.org
                Myron.Schwartz@mountsinai.org
                Parissa.Tabrizian@mountsinai.org
                Bachir.Taouli@mountsinai.org
                Sara.Lewis@mountsinai.org
                Journal
                Cancer Imaging
                Cancer Imaging
                Cancer Imaging
                BioMed Central (London )
                1740-5025
                1470-7330
                3 July 2020
                3 July 2020
                2020
                : 20
                : 43
                Affiliations
                [1 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Department of Diagnostic, Molecular and Interventional Radiology, , Icahn School of Medicine at Mount Sinai, ; One Gustave L. Levy Place, Box 1234, New York, NY 10029-6574 USA
                [2 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, ; New York, NY USA
                [3 ]GRID grid.5386.8, ISNI 000000041936877X, Department of Radiology, , Weill Cornell Medicine, ; New York, NY USA
                [4 ]GRID grid.240324.3, ISNI 0000 0001 2109 4251, Department of Radiology, , New York University Langone Medical Center, ; New York, NY USA
                [5 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, ; New York, NY USA
                Article
                323
                10.1186/s40644-020-00323-0
                7333305
                32620153
                801aa3bc-ba0d-490e-b488-d7b3f4bf82af
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 11 February 2020
                : 29 June 2020
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                bile duct cancer,texture,magnetic resonance imaging (mri),computed tomography (ct),survival

                Comments

                Comment on this article